 | Up a level |
Journal Article
Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V and Kunzmann, V (2022). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open, 7 (4). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Hartlapp, I., Valta-Seufzer, D., Siveke, J., Alguel, H., Goekkurt, E., Siegler, G. M., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C-T., Stang, H. A., Heinemann, V. and Kunzmann, V. (2021). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). Ann. Oncol., 32. S. S1091 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Kruger, S. F., Lohneis, A., Abendroth, A., Berger, A. W., Ettrich, T. J., Waidmann, O., Kapp, M., Steiner, B., Kumbrink, J., Reischer, A., Haas, M., Westphalen, C. B., Zhang, D., Miller-Phillips, L., Burger, P. J., Kobold, S., Werner, J., Subklewe, M., Von Bergwelt-Baildon, M., Kunzmann, V, Seufferlein, T., Siveke, J. T., Sinn, M., Heinemann, V, Ormanns, S. and Boeck, S. (2022). Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Perkhofer, L., Striefler, J. K., Sinn, M., Opitz, B., Goetze, T. O., Gallmeier, E., von Weikersthal, L. Fischer, Jacobasch, L., Waldschmidt, D., Niedermeier, M., Sohm, M., Sookthai, D., Berger, A., Beutel, A., Seufferlein, T. and Ettrich, T. J. (2021). Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Ann. Oncol., 32. S. S1282 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C. and Ettrich, T. J. (2023). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol., 34 (1). S. 91 - 101. AMSTERDAM: ELSEVIER. ISSN 1569-8041